XETRA - Delayed Quote EUR

Biotest Aktiengesellschaft (BIO3.DE)

30.00

0.00

(0.00%)

As of 2:41:02 PM GMT+2. Market Open.

Biotest AG (WBO:BIO3) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Biotest AG reports a 35% revenue increase and FDA approval for Yimmugo, setting the stage for U.S. market entry in 2025.

GuruFocus.com 7 months ago

BTTAY
Biotest wins FDA approval for plasma protein therapy

The US Food and Drug Administration (FDA) approved Biotest’s Yimmugo for the treatment of primary antibody deficiencies.

Pharmaceutical Technology 10 months ago

BTTAY

GRFS

Performance Overview

Return	BIO3.DE	DAX P (^GDAXI)
YTD	+11.11%	+18.49%
1-Year	+8.70%	+25.01%
3-Year	-15.37%	+68.16%